肿瘤防治研究2017，Vol.44Issue(7)：485-488,4.DOI:10.3971/j.issn.1000-8578.2017.16.1530
CEA、 CYFRA21-1、 NSE水平与EGFR突变的晚期肺腺癌患者临床疗效的相关性
Correlation of Tumor Markers with Clinical Efficacy of Advanced Lung Adenocarcinoma Patients with EGFR Mutation
卢畅 1申淑景 2毛玉焕 1冀瑛瑛 1李培培 1曹慧 1王晔 1李醒亚1
作者信息
- 1. 450052郑州,郑州大学第一附属医院肿瘤科
- 2. 450052郑州,郑州大学第一附属医院放疗科
- 折叠
摘要
Abstract
Objective To explore the correlation of serum tumor markers expression with the mutation rate and efficacy of the patients with EGFR-positive advanced lung adenocarcinoma.Methods We selected 143 patients who were molecular pathologically diagnosed as positive EGFR mutation had received epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) treatment.According to CYFRA21-1,CEA and NSE expression levels before treatment,the patients were randomly divided into high level group and normal level group,respectively.We retrospectively analyzed progression-flee survival(PFS) after the targeted therapy to explore the relationship between tumor markers expression before treatment and the efficacy of EGFR-TKIs as the first-line treatment on non-small cell lung cancer patients.Results The efficacy of high CEA group was significantly better than that of normal CEA group(P＜0.05).The curative effect of normal CYFRA21-1 group was longer than that of high CYFRA21-1 group(P＜0.05).The median PFS had no significant difference between high NSE group and normal NSE group(P＞0.05).In subgroup analysis,ECOG PS＜2 group was better than PS ≥ 2 group in PFS(P＜0.05).Non-smoking history group was better than smoking history group in curative effect(P＜0.05).Gender,age,TNM stage,mutation type and targeted drug had no significant differences in statistics.Multivariate survival analysis showed that median PFS was not related with ECOG PS score,smoking history or the state of CYFRA21-1,and the high expression of CEA was an independent prognostic factor for EGFR-TKIs as the first-line treatment.Conclusion High CEA has a certain correlation with EGFR mutation status.It is a positive independent prognostic factor for the evaluation of targeted therapy.关键词
肺腺癌/肿瘤标志物/EGFR突变/无进展生存期Key words
Lung adenocarcinoma/Tumor markers/EGFR mutation/ PFS分类
医药卫生引用本文复制引用
卢畅,申淑景,毛玉焕,冀瑛瑛,李培培,曹慧,王晔,李醒亚..CEA、 CYFRA21-1、 NSE水平与EGFR突变的晚期肺腺癌患者临床疗效的相关性[J].肿瘤防治研究,2017,44(7):485-488,4.
